PepGen Q2 net loss $19.5M; cash $147M; FDA clinical hold on DM1 trial continues

PepGen Inc.

2023-Q2 EPS reported -$1.51

Net loss of $19.5M for Q2 2023 vs $17.3M YoY; R&D expense $16.9M, G&A $4.2M.
Cash and equivalents $147.0M as of June 30, 2023; runway into early 2025.
FDA clinical hold remains on IND for PGN-EDODM1 Phase 1 study; working to lift.
Phase 2 CONNECT1-EDO51 open-label MAD study dosing patients in Canada H2 2023.
Phase 2 CONNECT2-EDO51 multinational RCT expected to initiate H2 2023; initial data mid-2024.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

PepGen Inc. reported the second quarter ended June 30, 2023 results: net income Net loss was $19.5 million for the three months ended June 30, 2023.

Period: the second quarter ended June 30, 2023
Net income: Net loss was $19.5 million for the three months ended June 30, 2023
Result: reported results

Exact text from the filing

PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today reported financial results for the second quarter ended June 30, 2023 and highlighted recent corporate developments.

View on SEC.gov

168 earnings releases filed in the last 30 days. Browse all earnings releases →

PepGen Inc. filing history →

Source: SEC EDGAR

accession 0000950170-23-039391

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.